Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877086 | 0.86 | EPHX2 (0.61) | ALDH1A1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2864934 | 0.82 | TSHR (0.49) | EPHX2TSHR | |
| SCHEMBL2861620 | 0.81 | CTRB1 (0.51) | ALDH1A1EPHX2NPC1RAB9A | |
| SCHEMBL2875665 | 0.80 | EPHX2 (0.53) | ALDH1A1CYP2C19EPHX2RAB9APOLB | |
| SCHEMBL2861732 | 0.78 | EPHX2 (0.62) | ALDH1A1CYP2C19EPHX2NPC1RAB9A | |
| SCHEMBL13169536 | 0.77 | EPHX2 (0.83) | ALDH1A1CYP2C19EPHX2EPHX1NPC1 | |
| SCHEMBL3455859 | 0.77 | EPHX2 (0.83) | ALDH1A1CYP2C19EPHX2EPHX1NPC1 | |
| SCHEMBL3372476 | 0.76 | LMNA (0.49) | NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2861403 | 0.75 | L3MBTL1 (0.49) | ALDH1A1EPHX2EPHX1NPC1RAB9A | |
| SCHEMBL3281866 | 0.75 | EPHX2 (0.54) | EPHX2EPHX1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | ALDH1A1 4075/4885CYP2C19 4003/4885EPHX2 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.